Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 2/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5084605 | 0.83 | NPSR1 (0.41) | SMN1; SMN2NPSR1LMNAMEN1KMT2A | |
| SCHEMBL9154034 | 0.83 | NPSR1 (0.41) | SMN1; SMN2NPSR1LMNAMEN1KMT2A | |
| SCHEMBL22581230 | 0.83 | SMN1; SMN2 (0.32) | SMN1; SMN2NPSR1LMNAMEN1KMT2A | |
| SCHEMBL14075738 | 0.83 | MEN1 (0.37) | MEN1KMT2A | |
| SCHEMBL5608918 | 0.80 | NPSR1 (0.51) | SMN1; SMN2NPSR1LMNAMEN1KMT2A | |
| SCHEMBL19357066 | 0.78 | SMN1; SMN2 (0.41) | SMN1; SMN2NPSR1LMNAMEN1KMT2A | |
| SCHEMBL20851056 | 0.78 | SMN1; SMN2 (0.41) | SMN1; SMN2NPSR1LMNAMEN1KMT2A | |
| SCHEMBL26111862 | 0.76 | MEN1 (0.35) | SMN1; SMN2NPSR1LMNAMEN1KMT2A | |
| SCHEMBL19639618 | 0.75 | GRM1 (0.37) | MEN1KMT2A | |
| SCHEMBL5608250 | 0.75 | NPSR1 (0.35) | NPSR1LMNAMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12049460-B2 | EGFR inhibitor compounds | RECURIUM IP HOLDINGS, LLC (US) | 2024-07-30 | — | — | US | disclosed |
| EP-3464275-B1 | EGFR INHIBITOR COMPOUNDS | RECURIUM IP HOLDINGS LLC (US) | 2024-05-08 | — | — | EP | disclosed |
| US-20210395230-A1 | EGFR INHIBITOR COMPOUNDS | RECURIUM IP HOLDINGS, LLC (US) | 2021-12-23 | — | — | US | disclosed |
| US-20200181120-A1 | EGFR INHIBITOR COMPOUNDS | KALYRA PHARMACEUTICALS, INC. | 2020-06-11 | — | — | US | disclosed |
| US-20170342055-A1 | EGFR INHIBITOR COMPOUNDS | RECURIUM IP HOLDINGS, LLC | 2017-11-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200181120-A1 | EGFR INHIBITOR COMPOUNDS | EGFR, ERBB2, ERBB3 | SMN1; SMN2 4789/4885NPSR1 2252/4885LMNA 4476/4885 |
| US-20170342055-A1 | EGFR INHIBITOR COMPOUNDS | EGFR, ERBB2, ERBB3 | SMN1; SMN2 4789/4885NPSR1 2252/4885LMNA 4476/4885 |
| US-12049460-B2 | EGFR inhibitor compounds | EGFR, ERBB2, ERBB3 | SMN1; SMN2 4585/4885NPSR1 1405/4885LMNA 4750/4885 |
| US-20210395230-A1 | EGFR INHIBITOR COMPOUNDS | EGFR, ERBB2, ERBB3 | SMN1; SMN2 4789/4885NPSR1 2252/4885LMNA 4476/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.